AI Article Synopsis
- Immunotherapy for gastrointestinal (GI) tract cancers has gained significant importance, especially through the use of immune checkpoint inhibitors (ICIs) like PD-1 and PD-L1 antibodies.
- Currently, a combination of anti-PD-1 with chemotherapy is the preferred first-line treatment for various advanced GI cancers, including gastric/gastroesophageal junction adenocarcinoma, dMMR/MSI-H colorectal cancer, and advanced esophageal cancer.
- Despite these advancements, researchers are still working to enhance the precision and effectiveness of immunotherapy for GI tumors, while also exploring innovative approaches like CAR-T therapy targeting claudin18.2 for later-line treatments.
Article Abstract
The past few decades have witnessed the rise of immunotherapy for Gastrointestinal (GI) tract cancers. The role of immune checkpoint inhibitors (ICIs), particularly programmed death protein 1 (PD-1) and PD ligand-1 antibodies, has become increasingly pivotal in the treatment of advanced and perioperative GI tract cancers. Currently, anti-PD-1 plus chemotherapy is considered as first-line regimen for unselected advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJC), mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer (CRC), and advanced esophageal cancer (EC). In addition, the encouraging performance of claudin18.2-redirected chimeric antigen receptor T-cell (CAR-T) therapy in later-line GI tract cancers brings new hope for cell therapy in solid tumour treatment. Nevertheless, immunotherapy for GI tumour remains yet precise, and researchers are dedicated to further maximising and optimising the efficacy. This review summarises the important research, latest progress, and future directions of immunotherapy for GI tract cancers including EC, G/GEJC, and CRC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11316403 | PMC |
| http://dx.doi.org/10.1186/s13045-024-01578-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient-derived xenograft models of gastrointestinal stromal tumors: a ready-to-use platform for translational research.
Dis Model Mech
January 2025
Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium.
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal malignancy of the gastrointestinal tract. Most GIST harbor mutations in oncogenes, such as KIT, and are treated with tyrosine kinase inhibitors (TKI), such as imatinib. Most tumors develop secondary mutations inducing drug resistance against the available TKI, which requires novel therapies.
View Article and Find Full Text PDFFormulation of Hydrogel Beads to Improve the Bioaccessibility of Bioactive Compounds from Goldenberry and Purple Passion Fruit and Evaluation of Their Antiproliferative Effects on Human Colorectal Carcinoma Cells.
Gels
December 2024
Group of Toxicology, Food and Therapeutic Alternatives, College of Pharmaceutical and Food Sciences, University of Antioquia UdeA, Calle 67, Medellin 053108, Colombia.
Goldenberry and purple passion fruit contain bioactive compounds (BCs) that can prevent gastrointestinal cancers; hydrogel beads can protect and control their release in the gastrointestinal tract. This study aimed to develop an encapsulating material for fruit hydrogel beads (FHBs) to increase their bioaccessibility and to assess antiproliferative effects. A blend of goldenberry-purple passion fruit was encapsulated using ionic gelation and electrospraying.
View Article and Find Full Text PDFImpact of Bone-Modifying Agents on Post-Bone Metastasis Survival Across Cancer Types.
Curr Oncol
January 2025
Department of Orthopedic Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Background: Bone metastasis is associated with a poor prognosis. Bone-modifying agents (BMA) are commonly used for the prevention or treatment of skeletal-related events (SRE) in patients with bone metastasis; however, whether or not treatment with BMA improves survival remains unclear. In this study, we investigated whether BMA was involved in post-bone metastasis survival.
View Article and Find Full Text PDFThe Immune Landscape and Its Potential for Immunotherapy in Advanced Biliary Tract Cancer.
Curr Oncol
December 2024
Gastrointestinal Unit, The Royal Marsden Hospital, London SW3 6JJ, UK.
Biliary tract cancers (BTC) are a highly heterogeneous group of cancers at the genomic, epigenetic and molecular levels. The vast majority of patients initially present at an advanced (unresectable) disease stage due to a lack of symptoms and an aggressive tumour biology. Chemotherapy has been the mainstay of treatment in patients with advanced BTC but the survival outcomes and prognosis remain poor.
View Article and Find Full Text PDFPotentials of N-Acyl hydrazones Against Colorectal Cancer: A Mini Review.
Anticancer Agents Med Chem
January 2025
Department of Natural Products and Medicinal Chemistry, CSIR-Indian Institute of Chemical Technology, Tarnaka, Uppal Road, Hydrabad, 500037, India.
Colorectal cancer (CRC) is a malignant gastrointestinal tract disorder with high occurrence and mortality index and showing an upsurge. Standard therapies for treating CRC are surgery and chemotherapy. Despite great effort in developing effective treatments, the progress is limited due to its relapse and recurrence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!